WeVote
Log In

Bill

Bill

A 7501

Adds tianeptine sodium to the list of Schedule II of controlled substances

2025 Regular Session Introduced by Ed Braunstein

Adds tianeptine sodium to New York's Schedule II, imposing registration, prescribing, recordkeeping, and enforcement—tightening access for doctors, pharmacists, and patients.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 7501

Summary of Assembly Bill A-7501

Overview

  • Bill: A-7501
  • Title: Adds tianeptine sodium to the list of Schedule II controlled substances
  • Status: Referred to Health
  • Introduced: March 28, 2025
  • Sponsor: Edward Braunstein (primary)
  • Jurisdiction: Assembly (New York) with a Senate companion referenced as S 3351

What the bill does

  • The bill adds tianeptine sodium to Schedule II of the state’s controlled substances schedule.
  • Schedule II designation typically entails strict regulatory controls, reflecting a high potential for abuse with medical use and severe restrictions on dispensing and prescribing.

Key provisions and regulatory implications

  • By placing tianeptine sodium in Schedule II, it would become subject to the state’s existing Schedule II controls, which generally include:
    • Requirements for registration and licensing of manufacturers, distributors, and dispensers
    • Strict prescribing rules (e.g., limitations on refills, documentation, and dispensing practices)
    • Enhanced recordkeeping and reporting obligations
    • Enforcement provisions with penalties for illicit manufacture, distribution, or possession
  • The bill does not detail additional new provisions in the text provided, but Schedule II placement typically activates these regulatory safeguards.

Who and what is affected

  • Manufacturers, wholesalers, pharmacies, and medical practitioners would operate under heightened controls for tianeptine sodium.
  • Patients and consumers could experience restricted access or changes in how tianeptine sodium is prescribed or dispensed if it is used medically in the state (though tianeptine sodium is not widely approved as a mainstream medical treatment in every jurisdiction).
  • Law enforcement and regulatory agencies would enforce Schedule II compliance and respond to violations.

Procedural and timeline notes

  • The bill has been referred to the Health Committee on March 28, 2025 (noting two identical entries for the same action, which appears to be a clerical duplication).
  • Companion relationships: A companion Senate bill exists (S 3351), with related Assembly counterparts in prior sessions (A 7550, A 344, A 9188). This suggests ongoing consideration of tianeptine sodium scheduling across sessions.

Potential impact to watch

  • If enacted, the state would implement stricter controls on tianeptine sodium, potentially reducing misuse and diversion but also potentially affecting legitimate access and prescribing practices.
  • Stakeholders to monitor include healthcare providers, pharmacists, public health advocates, and law enforcement, as well as any entities involved in the production or distribution of tianeptine sodium.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.